Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus DOCEFREZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus DOCEFREZ.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs DOCEFREZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Docetaxel binds to beta-tubulin, promoting microtubule assembly and inhibiting depolymerization, resulting in cell cycle arrest at G2/M phase and apoptosis.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
75 mg/m² intravenously over 1 hour every 3 weeks.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Terminal elimination half-life is 4.5-6.0 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Primarily renal excretion (70-80% as unchanged drug) with hepatic metabolism contributing to biliary/fecal elimination (20-30%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic